discordant results, have examined the clinical impact of preoperative MR on outcome after TAVR, and there are no direct comparisons of the impact of SAVR and TAVR. [13] [14] [15] We examined the impact of moderate and severe MR on outcomes after TAVR and SAVR in cohort A of the randomized, multicenter Placement of Aortic Transcatheter Valve (PARTNER) trial.
Methods

Study Design and Population
The design of the PARTNER trial has been reported previously. 16, 17 Briefly, the PARTNER study enrolled patients with severe symptomatic aortic stenosis (n=1057). There were 2 individually powered patient cohorts. In Cohort A, the balloon-expandable Edwards SAPIEN prosthesis was compared with SAVR in high-risk patients; patients enrolled in this cohort were randomized to TAVR (transfemoral if iliac and femoral vessels were suitable or transapical if not) or to conventional SAVR. In cohort B, the Edwards SAPIEN device was compared with medical management in inoperable patients. The present analysis includes patients undergoing either TAVR (n=331) or SAVR (n=299) enrolled in cohort A (operable high-risk patients) of the PARTNER trial. All the analyses were performed in the "astreated" population because the aims of the study were to assess the impact of concomitant preoperative MR on outcomes after TAVR and SAVR and to determine the degree of improvement in MR after intervention. Although mitral repair or replacement was precluded in the SAVR patients according to the PARTNER protocol, some patients underwent mitral valve intervention (protocol deviation) and were also excluded from the analysis of MR change at follow-up (n=7). Both TAVR and SAVR patients were dichotomized according to the degree of preoperative MR (moderate/severe versus none/trace/mild). Although patients with severe MR were excluded by the protocol, some were included in the study because of either changing hemodynamics on qualifying versus baseline echocardiography or discordant site and core laboratory assessments of MR severity.
According to the study protocol, transthoracic 2-dimensional echocardiograms were performed at baseline; discharge; 1, 6, and 12 months; and then yearly after the procedure. Transthoracic echocardiograms included assessment of aortic valve hemodynamics (gradients, area, and indexed area); degree of regurgitation; cardiac output and cardiac index; left ventricular (LV) systolic function, volumes, and diameters; and mitral valve degree of regurgitation and leaflet thickening. MR severity was graded as none, trace, mild, moderate, or severe according to the American Society of Echocardiography recommendations, integrating structural, Doppler, and quantitative parameters. 18 All echocardiographic images were analyzed by an independent echocardiography core laboratory (Duke University Medical Center, Durham, NC) as previously described. 19 κ Statistics assessing the reproducibility of MR measurement among physician overreaders were 0.74 to 0.85 for intraobserver variability and 0.85 for interobserver variability. All adverse events were adjudicated by an independent clinical events committee. All data were sent for analysis to an independent academic biostatistics group (Department of Statistics, Columbia University, New York, NY).
Statistical Analysis
All continuous variables were analyzed by mean, standard deviation, and 2-sample t test. If data were not normally distributed, the MannWhitney U test was used instead. All categorical variables were analyzed by frequency, percent, and χ 2 test or Fisher exact test when asymptotic validity was not met. All time data were analyzed with Kaplan-Meier methodology and log-rank test, and hazard ratio estimates correspond to Cox proportional hazards modeling. The following variables were included in the Cox proportional hazards modeling for all-cause death: age, female sex, malignant tumor, previous balloon aortic valvuloplasty, peripheral vascular disease, previous myocardial infarction, baseline LV ejection fraction, and baseline LV end-systolic diameter. Landmark analysis was also performed with the prespecified windows of date of the procedure to day 30 and day 30 to 2 years. A sensitivity analysis was performed excluding the 13 patients (7 TAVR and 6 SAVR) with severe preoperative MR. A second sensitivity analysis was also performed excluding the 7 patients with concomitant mitral valve intervention (protocol deviation), with the hypothesis that results could be affected by this important variable. However, no differences were found, and the results presented include the entire randomized as-treated population.
Data are based on an extract date of November 11, 2012. All statistical analysis was performed with SAS software, version 9.2 (SAS Institute, Cary, NC).
Results
Patients and Baseline Characteristics
The clinical characteristics of the study population are summarized in Table 1 
Clinical Outcomes
Among the SAVR group, 5 patients (5.8%) with periprocedural moderate/severe MR underwent concomitant MV repair and 1 patient with periprocedural mild MR and severe mitral stenosis underwent MV replacement. In the TAVR group, 1 patient with no MR and severe mitral stenosis underwent concomitant MV balloon valvuloplasty. The in-hospital all-cause mortality among SAVR patients with moderate or severe MR was almost double that of patients with no/mild preoperative MR, although this difference was not significant (15.9% versus 8.1%; P=0.11). The degree of MR at baseline did not affect all-cause mortality in TAVR patients (6.2% versus 4.9%, moderate/severe versus none/mild; P=0.75; Figure 1) .
Clinical outcomes at 30 days, 1 year, and 2 years are shown in Figure 2B and Table 2 ). In addition, patients with moderate or severe MR had a greater incidence of major bleeding (41.1% versus 26.0%; P=0.02). The 30-day landmark analyses for all-cause mortality in both TAVR and SAVR are shown in Figure 3 . A consistent pattern of no significant mortality difference in TAVR patients with moderate/ severe MR was found both during the first 30 days and from 30 days to 2 years. On the other hand, SAVR patients with moderate/severe MR had a trend toward higher mortality at 30 days compared with patients with no/mild MR (13.6% versus 7.1%, HR, 2.01; 95% CI, 0.87-4.67; P=0.09) and a significantly higher mortality rate between 30 days and 2 years (41.1% versus 22.4%; HR, 1.95; 95% CI, 1.16-3.27; December 24/31, 2013 P=0.01). Interaction tests showed remarkable effect of perioperative moderate/severe MR on 2-year all-cause mortality between TAVR and SAVR, although this was not statistically significant (P for interaction=0.05). A secondary analysis was also carried out pooling TAVR patients enrolled in cohorts A and B (n=499) and comparing this group with the SAVR group (see the online-only Data Supplement). In this case, the 2 groups still had similar baseline characteristics, and interaction tests showed significant effects of perioperative moderate/severe MR on 2-year all-cause mortality between TAVR and SAVR (P for interaction=0.02). Both TAVR and SAVR patients experienced an improvement in heart failure-related symptoms. Changes in New York Heart Association functional class over time among all groups are depicted in Figure 4 . At follow-up, 1 TAVR patient with perioperative moderate MR underwent surgical mitral valve replacement along with SAVR as a result of moderate to severe paravalvular aortic valvular regurgitation. None of patients of the SAVR cohort A group underwent any intervention (surgical or percutaneous) on the mitral valve at follow-up.
Echocardiographic Outcomes
Baseline echocardiographic data are summarized in Table 3 . Figure 5 shows the change in MR in the TAVR and SAVR patients. At 30 days, among survivors who had isolated SAVR/TAVR, moderate/severe MR had improved in 25 SAVR patients (69.4%) and 30 TAVR patients (57.7%), was unchanged in 10 SAVR patients (27.8%) and 19 TAVR patients (36.5%), and worsened in 1 SAVR patient (2.8%) and 4 TAVR patients (5.8%) (all P=NS).
During follow-up, all patients, regardless of treatment modality (TAVR or SAVR) or severity of preoperative MR, experienced a modest increase in LV ejection fraction and a significant reduction in LV mass and volumes (Table 4) . This finding was consistent in both the TAVR and SAVR groups. Patients with moderate or severe MR had no statistically significant change in LV end-diastolic volume over time.
Univariate analysis was conducted to look for any clinical and echocardiographic predictors of MR improvement. The following variables were tested: previous myocardial infarction; previous coronary artery bypass grafting or percutaneous coronary intervention; age; atrial fibrillation; baseline and discharge LV ejection fraction, mass, volumes, and diameters; pretreatment and posttreatment mean transaortic gradient; and mitral valve leaflet thickening. LV end-diastolic diameter (odds ratio, 5.42; 95% CI, 1.25-3.42; P=0.02) at discharge was found to be associated with MR improvement. However, no variables were found to be significant when tested by multivariate analysis.
Discussion
Significant MR is often found in combination with severe aortic stenosis. [1] [2] [3] 6, 7 The findings of the present analysis, performed on the as-treated population of cohort A of the PARTNER trial, add considerably to the understanding of the impact of moderate/severe MR in high-risk patients undergoing isolated TAVR and SAVR. Importantly, improvements in symptoms and functional class were found with both TAVR and SAVR, regardless of the severity of MR.
However, the importance of significant MR appears to differ in patients undergoing TAVR or SAVR. Despite significant baseline differences between the MR severity groups, both SAVR and TAVR cohorts experienced similar changes in LV remodeling and improvement in LV function. Moderate or severe MR in patients undergoing SAVR, however, was associated with a trend toward higher early mortality and a significant increase in late mortality. Similarly, Barreiro and coworkers, 3 in a retrospective review of 408 patients undergoing isolated SAVR, found that moderate MR was an independent risk factor for late survival. A recent meta-analysis of 3053 patients undergoing isolated SAVR found that moderate or severe MR was associated with worse early and late survival. 7 In contrast, moderate or severe MR did not affect mortality in patients undergoing TAVR. At 30 days, moderate or greater MR was associated with a significantly lower mortality with TAVR than with SAVR (4.6% versus 12.5%). A landmark analysis 20 showed that there is a consistency in terms of both early (from the procedure to 30 days) and late (from 30 days to 2 years) outcomes after TAVR. Interestingly, a secondary analysis (see the online-only Data Supplement) performed combining cohorts A and B TAVR patients did not alter the results.
As in the present study, D'Onofrio et al 15 found that moderate or severe MR did not appear to be a significant risk factor for in-hospital mortality after TAVR. In contrast, Toggweiler et al 14 found that moderate or severe MR in patients undergoing TAVR was associated with a higher early but not late mortality rate. This difference might be explained by the higher proportion of patients with preoperative severe MR in the Toggweiler et al analysis (10% versus 2%). 22 LV fractional area change, 25 less mitral annular calcification, 24 and the absence of atrial fibrillation 22 are associated with a higher probability of a reduction in MR after isolated SAVR. Similarly, Toggweiler et al 14 found that functional MR, a low mean aortic gradient (<40 mm Hg), and the absence of severe pulmonary hypertension or atrial fibrillation were associated with a higher probability of MR improvement after TAVR.
Finally, the presence of persistent moderate/severe MR did not prevent significant LV remodeling, as demonstrated by the reduction in LV mass and volumes and the increase in ejection fraction 1 year after intervention. This finding was consistent in both the TAVR and SAVR groups.
Study Limitations
This is the first study of MR in the setting of TAVR to include core laboratory echocardiographic evaluation. However, the PARTNER trial protocol did not incorporate a detailed analysis of mitral valve morphology or function sufficient to confidently identify the mechanism of MR, nor was MR analyzed with quantitative parameters, which may limit our ability to predict which specific patients are more likely to have consistent MR improvement after AVR. Severe MR was an exclusion criterion in the PARTNER trial. Consequently, this analysis included predominantly patients with moderate rather than severe MR. A sensitivity analysis performed excluding all patients with baseline severe MR (7 in the TAVR group and 6 in the SAVR group) showed no impact on outcomes. Changes in echocardiographic parameters such as degree of MR and LV ejection fraction, mass, volumes, and diameters may be subject to survivor bias and may therefore be overestimated. Finally, 6 of 7 patients with a reported protocol deviation and concomitant mitral valve intervention were in the SAVR cohort. Although a second sensitivity analysis performed excluding all MV intervention patients showed no impact on outcomes, these patients were necessarily excluded in the assessment of between-group changes in MR. This strategy may potentially bias the results in favor of the SAVR group because the patients with worse MR or MR related to structural issues (ie, flail leaflet) were excluded, potentially resulting in a cohort of patients whose MR was more likely to improve after isolated SAVR.
Conclusions
Both TAVR and SAVR resulted in a significant early improvement in baseline MR. The response of MR to SAVR or TAVR is not predictable. Early improvement was greater among SAVR survivors, although this may reflect to some degree a higher mortality among SAVR patients with moderate or severe MR. Moderate or severe MR at baseline was associated with increased 2-year mortality after SAVR but not after TAVR. TAVR may be a reasonable option in selected patients with combined aortic and mitral valve disease. 
